2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner | 3,851,507 | Jan 11, 2023 |
| Hadley Harbor Master Investors (Cayman) L.P. | — | 470,588 | Nov 18, 2015 |
| Sandrock Alfred | CEO | 430,931 | Apr 4, 2025 |
| Turenne Andre | CEO | 322,375 | Mar 23, 2021 |
| Pfreundschuh Peter P. | CFO | 175,669 | Feb 22, 2024 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Feb 26, 2026 | Swartz Robin | COO | Sell | 46.3 | -6,458 | -3.13% | ✗ | $24.3K |
| Feb 24, 2026 | Feb 26, 2026 | Sandrock Alfred | CEO | Sell | 42.5 | -14,197 | -2.85% | ✗ | $53.8K |
| Feb 24, 2026 | Feb 26, 2026 | Jorgensen Nathan D. | CFO | Sell | 46.3 | -4,668 | -2.99% | ✗ | $17.6K |
| Feb 24, 2026 | Feb 26, 2026 | Carter Todd Alfred | Chief Scientific Officer | Sell | 46.3 | -4,174 | -2.78% | ✗ | $15.7K |
| Feb 18, 2026 | Feb 20, 2026 | Swartz Robin | COO | Sell | 46.3 | -3,882 | -1.85% | ✗ | $13.4K |
| Feb 18, 2026 | Feb 20, 2026 | Carter Todd Alfred | Chief Scientific Officer | Sell | 46.3 | -3,301 | -2.15% | ✗ | $11.4K |
| Feb 18, 2026 | Feb 20, 2026 | Sandrock Alfred | CEO | Sell | 46.3 | -11,732 | -2.30% | ✗ | $40K |
| Feb 10, 2026 | Feb 11, 2026 | Swartz Robin | COO | Sell | 46.3 | -4,569 | -2.13% | ✗ | $17.6K |
| Feb 10, 2026 | Feb 11, 2026 | Sandrock Alfred | CEO | Sell | 46.3 | -12,192 | -2.33% | ✗ | $46.1K |
| Feb 10, 2026 | Feb 11, 2026 | Carter Todd Alfred | Chief Scientific Officer | Sell | 46.3 | -3,525 | -2.25% | ✗ | $13.6K |
| Feb 6, 2026 | Feb 10, 2026 | Ferguson Toby | Chief Medical Officer | Neutral | 90.0 | +45,000 | 32.39% | ✗ | - |
| Feb 6, 2026 | Feb 10, 2026 | Carter Todd Alfred | Chief Scientific Officer | Neutral | 90.0 | +33,000 | 26.67% | ✗ | - |
| Feb 6, 2026 | Feb 10, 2026 | Swartz Robin | COO | Neutral | 90.0 | +45,000 | 26.53% | ✗ | - |
| Feb 6, 2026 | Feb 10, 2026 | Sandrock Alfred | CEO | Neutral | 90.0 | +86,250 | 19.79% | ✗ | - |
| Feb 6, 2026 | Feb 10, 2026 | Jorgensen Nathan D. | CFO | Neutral | 90.0 | +32,250 | 26.04% | ✗ | - |
| Jan 6, 2026 | Jan 8, 2026 | Shiferman Gregory L. | SVP and General Counsel | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 8, 2026 | Shiferman Gregory L. | SVP and General Counsel | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 3, 2025 | Oct 7, 2025 | Jorgensen Nathan D. | CFO | Sell | 46.3 | -7,666 | -5.83% | ✗ | $36.6K |
| Aug 18, 2025 | Aug 20, 2025 | Ferguson Toby | Chief Medical Officer | Sell | 22.5 | -19,000 | -12.03% | ✗ | $70.9K |
| Jun 3, 2025 | Jun 4, 2025 | Vitale Nancy | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 4, 2025 | SCANGOS GEORGE A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 4, 2025 | PIERCE GLENN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 4, 2025 | Onyia Jude | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 4, 2025 | MACKEY CATHERINE J | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 4, 2025 | Hyman Steven | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 4, 2025 | Higgins Michael J | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 4, 2025 | GERAGHTY JAMES A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 4, 2025 | Colon Grace | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 2, 2025 | Apr 4, 2025 | Ferguson Toby | Chief Medical Officer | Sell | 46.3 | -10,086 | -6.00% | ✗ | $34.6K |
| Apr 2, 2025 | Apr 4, 2025 | Sandrock Alfred | CEO | Sell | 46.3 | -10,885 | -2.46% | ✗ | $37.3K |
| Feb 20, 2025 | Feb 24, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 91.3 | +42,695 | 52.69% | ✗ | $14.1K |
| Feb 20, 2025 | Feb 24, 2025 | Sandrock Alfred | CEO | Sell | 91.3 | +133,298 | 43.21% | ✗ | $49.6K |
| Feb 20, 2025 | Feb 24, 2025 | Swartz Robin | COO | Sell | 91.3 | +67,356 | 65.85% | ✗ | $16.5K |
| Feb 21, 2025 | Feb 24, 2025 | Fahey Sandell Jacquelyn | Chief Legal Officer | Neutral | 90.0 | +41,500 | 50.83% | ✗ | - |
| Feb 21, 2025 | Feb 24, 2025 | Ferguson Toby | Chief Medical Officer | Neutral | 90.0 | +63,000 | 60.00% | ✗ | - |
| Feb 21, 2025 | Feb 24, 2025 | Jorgensen Nathan D. | CFO | Neutral | 90.0 | +51,500 | 64.38% | ✗ | - |
| Feb 11, 2025 | Feb 12, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 46.3 | -5,413 | -6.26% | ✗ | $24.1K |
| Feb 11, 2025 | Feb 12, 2025 | Swartz Robin | COO | Sell | 46.3 | -6,950 | -6.36% | ✗ | $30.9K |
| Feb 11, 2025 | Feb 12, 2025 | Sandrock Alfred | CEO | Sell | 42.5 | -16,644 | -5.12% | ✗ | $74.1K |
| Feb 11, 2025 | Feb 12, 2025 | Fahey Sandell Jacquelyn | Chief Legal Officer | Sell | 46.3 | -4,358 | -5.07% | ✗ | $19.4K |
| Jan 14, 2025 | Jan 15, 2025 | Swartz Robin | COO | Sell | 26.3 | -3,087 | -2.75% | ✗ | $15.7K |
| Jan 14, 2025 | Jan 15, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 27.5 | -1,191 | -1.36% | ✗ | $6.1K |
| Dec 23, 2024 | Dec 26, 2024 | Swartz Robin | COO | Sell | 26.3 | -6,500 | -5.47% | ✗ | $36.7K |
| Oct 2, 2024 | Oct 3, 2024 | Fahey Sandell Jacquelyn | Chief Legal Officer | Sell | 46.3 | -5,999 | -6.52% | ✗ | $34.9K |
| Oct 1, 2024 | Oct 2, 2024 | Jorgensen Nathan D. | CFO | Neutral | 90.0 | +80,000 | 100.00% | ✗ | - |
| Jul 8, 2024 | Jul 9, 2024 | Jorgensen Nathan D. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 9, 2024 | Jorgensen Nathan D. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 5, 2024 | Jun 7, 2024 | Vitale Nancy | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2024 | Jun 7, 2024 | SCANGOS GEORGE A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2024 | Jun 7, 2024 | PIERCE GLENN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2024 | Jun 7, 2024 | Onyia Jude | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2024 | Jun 7, 2024 | MACKEY CATHERINE J | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2024 | Jun 7, 2024 | Hyman Steven | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2024 | Jun 7, 2024 | Higgins Michael J | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2024 | Jun 7, 2024 | GERAGHTY JAMES A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2024 | Jun 7, 2024 | Colon Grace | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Ferguson Toby | Chief Medical Officer | Neutral | 90.0 | +105,000 | 100.00% | ✗ | - |
| Apr 2, 2024 | Apr 3, 2024 | Swartz Robin | COO | Sell | 46.3 | -1,357 | -1.15% | ✗ | $13.4K |
| Apr 2, 2024 | Apr 3, 2024 | Sandrock Alfred | CEO | Sell | 42.5 | -12,115 | -3.62% | ✗ | $119.5K |
| Mar 25, 2024 | Mar 26, 2024 | Ferguson Toby | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 26, 2024 | Ferguson Toby | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 21, 2024 | Feb 22, 2024 | Swartz Robin | COO | Sell | 46.3 | -3,966 | -3.24% | ✗ | $29.5K |
| Feb 21, 2024 | Feb 22, 2024 | Sandrock Alfred | CEO | Sell | 42.5 | -13,033 | -3.75% | ✗ | $97.2K |
| Feb 21, 2024 | Feb 22, 2024 | PFREUNDSCHUH PETER P. | CFO | Sell | 46.3 | -3,764 | -2.10% | ✗ | $28.1K |
| Feb 20, 2024 | Feb 22, 2024 | Carter Todd Alfred | Chief Scientific Officer | Sell | 46.3 | -3,967 | -4.33% | ✗ | $29.8K |
| Feb 9, 2024 | Feb 16, 2024 | Fahey Sandell Jacquelyn | Chief Legal Officer | Neutral | 90.0 | +31,000 | 50.82% | ✗ | - |
| Feb 9, 2024 | Feb 16, 2024 | Carter Todd Alfred | Chief Scientific Officer | Neutral | 90.0 | +38,500 | 72.51% | ✗ | - |
| Feb 9, 2024 | Feb 16, 2024 | Swartz Robin | COO | Neutral | 90.0 | +50,000 | 69.13% | ✗ | - |
| Feb 9, 2024 | Feb 16, 2024 | Sandrock Alfred | CEO | Neutral | 90.0 | +130,000 | 59.64% | ✗ | - |
| Feb 9, 2024 | Feb 16, 2024 | PFREUNDSCHUH PETER P. | CFO | Neutral | 90.0 | +30,000 | 20.08% | ✗ | - |
| Jan 17, 2024 | Jan 19, 2024 | Swartz Robin | COO | Sell | 46.3 | -2,543 | -3.40% | ✗ | $18.2K |
| Jan 17, 2024 | Jan 19, 2024 | Carter Todd Alfred | Chief Scientific Officer | Sell | 47.5 | -1,266 | -2.33% | ✗ | $9.1K |
| Oct 3, 2023 | Oct 5, 2023 | PFREUNDSCHUH PETER P. | CFO | Sell | 42.5 | -13,567 | -8.32% | ✗ | $94.8K |
| Oct 1, 2023 | Oct 2, 2023 | Fahey Sandell Jacquelyn | Chief Legal Officer | Neutral | 90.0 | +61,000 | 100.00% | ✗ | - |
| Sep 15, 2023 | Sep 18, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 20.0 | -10,500 | -16.19% | ✓ | $85.7K |
| Jul 10, 2023 | Jul 11, 2023 | Fahey Sandell Jacquelyn | Chief Legal Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 11, 2023 | Fahey Sandell Jacquelyn | Chief Legal Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jul 6, 2023 | Jul 10, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 28.8 | -5,500 | -8.41% | ✓ | $59.4K |
| Jun 30, 2023 | Jul 5, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 32.5 | -5,000 | -7.11% | ✓ | $57.1K |
| Jun 6, 2023 | Jun 7, 2023 | PIERCE GLENN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2023 | Jun 7, 2023 | MACKEY CATHERINE J | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2023 | Jun 7, 2023 | Vitale Nancy | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2023 | Jun 7, 2023 | Onyia Jude | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2023 | Jun 7, 2023 | Higgins Michael J | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2023 | Jun 7, 2023 | Colon Grace | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2023 | Jun 7, 2023 | GERAGHTY JAMES A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2023 | Jun 7, 2023 | SCANGOS GEORGE A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2023 | Jun 7, 2023 | Hyman Steven | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 9, 2023 | May 11, 2023 | SCANGOS GEORGE A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 11, 2023 | SCANGOS GEORGE A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 3, 2023 | Apr 5, 2023 | Sandrock Alfred | CEO | Sell | 42.5 | -7,437 | -3.35% | ✗ | $58.2K |
| Apr 3, 2023 | Apr 5, 2023 | Swartz Robin | COO | Sell | 47.5 | -1,259 | -1.73% | ✗ | $9.9K |
| Mar 20, 2023 | Mar 22, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 41.3 | -2,193 | -3.25% | ✓ | $17K |
| Mar 20, 2023 | Mar 22, 2023 | Swartz Robin | COO | Sell | 41.3 | -3,654 | -4.77% | ✓ | $28.4K |
| Mar 20, 2023 | Mar 22, 2023 | Hesslein Robert W. | Senior VP & General Counsel | Sell | 41.3 | -4,410 | -4.14% | ✓ | $34.2K |
| Mar 15, 2023 | Mar 17, 2023 | Swartz Robin | COO | Sell | 22.5 | -15,373 | -16.73% | ✗ | $126.1K |
| Feb 23, 2023 | Feb 27, 2023 | Onyia Jude | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 27, 2023 | Onyia Jude | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 17, 2023 | Feb 22, 2023 | Hesslein Robert W. | Senior VP & General Counsel | Sell | 45.0 | -3,297 | -3.00% | ✓ | $24.6K |
| Feb 17, 2023 | Feb 22, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 90.0 | +33,262 | 97.00% | ✓ | $5.5K |